Table 2.

Encounter characteristics of the training, validation, and testing cohorts

Characteristics	Training cohort (N = 303)	Validation cohort (N = 101)	Testing cohort (N = 104)	p-value train versus Test*	p-value validation versus test*	p-value train + validation versus test*
Number of unique patients N (%)	288 (95.0)	96 (95.0)	97 (93.3)
Primary outcome (N, (%))
Mortality	43 (14.2)	6 (5.9)	11 (10.6)	0.18	0.12	< 0.0001
Demographics
Age in years Mean (std)	56.6 (16.6)	56.6 (15.6)	53.4 (14.2)	0.012	0.028	0.009
Female N (%)	147 (48.5)	50 (49.5)	56 (53.8)	0.18	0.27	0.18
Race/ethnicity (N, (%))				0.63	0.95	0.76
Black	137 (45.2)	51 (50.5)	49 (47.1)
Hispanic	36 (11.9)	13 (12.9)	16 (15.4)
Other, non- hispanic	112 (37.0)	30 (29.7)	32 (30.7)
White	18 (5.9)	7 (6.9)	7 (6.7)
Mean (std) of the number of laboratory measurements per encounter
	636 (786)	510 (663)	531 (972)	0.078	0.228	0.090
Mean (std) vital signs measurements per encounter
	999 (1540)	765 (1344)	802 (1971)	0.026	0.12	0.030
Comorbidities				0.81	0.69	0.81
Mean (std) comorbidities per encounter	1.0 (1.1)	1.0 (1.1)	0.9 (0.9)
Hypertension N (%)	128 (42.2)	43 (42.6)	37 (35.6)
Diabetes N (%)	89 (29.4)	32 (31.7)	30 (28.8)
Heart disease N (%)	12 (3.9)	1 (1.0)	2 (1.9)
COPD N (%)	3 (1.0)	0 (0.0)	1 (1.0)
Stroke N (%)	1 (0.3)	0 (0.0)	0 (0.0)
Cerebrovascular disease N (%)	0 (0.0)	2 (2.0)	0 (0.0)
Cancer N (%)	4 (1.3)	2 (2.0)	1 (1.0)
Respiratory problems N (%)	44 (14.5)	12 (11.9)	15 (14.4)
Chronic kidney disease N (%)	28 (9.2)	11 (10.9)	6 (5.7)
Tuberculosis N (%)	3 (1.0)	1 (1.0)	3 (2.9)

Bold indicates p-value < 0.05

Significance was set at 0.05

Patients older than 89 have been clipped to age 90

^*Continuous variables were compared using a t-test and categorical variables were compared using a Chi-square test